Filing Details

Accession Number:
0001415889-13-001821
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-09-13 17:56:31
Reporting Period:
2013-09-12
Filing Date:
2013-09-13
Accepted Time:
2013-09-13 17:56:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1291623 L Leslie Iversen 11085 Torreyana Road #100
San Diego CA 92121
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-09-12 4,500 $6.10 18,000 No 4 M Direct
Common Stock Acquisiton 2013-09-12 10,000 $1.30 28,000 No 4 M Direct
Common Stock Acquisiton 2013-09-12 45,500 $1.30 73,500 No 4 M Direct
Common Stock Disposition 2013-09-12 60,000 $22.92 13,500 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2013-09-12 4,500 $0.00 4,500 $6.10
Common Stock Stock option (right to buy) Disposition 2013-09-12 10,000 $0.00 10,000 $1.30
Common Stock Stock option (right to buy) Disposition 2013-09-12 45,500 $0.00 45,500 $1.30
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2014-06-13 No 4 M Direct
0 2020-06-10 No 4 M Direct
29,500 2020-06-10 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2013.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.64 to $23.30 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
  3. 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following March 12, 2004.
  4. 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 11, 2010.